Meeting
2017 ASCO Annual Meeting
Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer after chemotherapy for metastatic disease—MONARCH 1.
Authors
Mark Boye
Eli Lilly and Company, Greenwood, IN
Mark Boye , Katherine Houghton , Donald E Stull , Claire Ainsworth , Gregory L Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02102490
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1060)
DOI
10.1200/JCO.2017.35.15_suppl.1060
Abstract #
1060
Poster Bd #
52
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.
First Author: Sonia Pernas
Poster
2023 ASCO Annual Meeting
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
First Author: Timothy A. Yap
Poster
2023 ASCO Annual Meeting
A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.
First Author: Stephen Joseph Bagley
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel